價(jià)格 | ¥218 | ¥496 | ¥745 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱(chēng):化合物 RK-33 | 英文名稱(chēng):RK33 |
CAS:1070773-09-9 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 97.55% | 產(chǎn)品類(lèi)別: 抑制劑 |
貨號(hào): T6970 |
名稱(chēng) | RK33 |
描述 | RK33 (RK 33) is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells. |
細(xì)胞實(shí)驗(yàn) | Healthy, 60-70% confluent MDA-MB-231 cells are transduced with shDDX3 lentivirus particles. Knockdown of DDX3 expression is confirmed both by qRT-PCR and immunoblotting. MDA-MB-231 cells are treated with RK-33 (7.5 μM) for 12 h and harvested for RNA. Microarray experiments are performed.(Only for Reference) |
體外活性 | RK-33 binds specifically to DDX3, but not to the closely related proteins DDX5 and DDX17. RK-33 inhibits cancer growth and radiosensitizes lung cancer cells in a DDX3-dependent manner. RK-33 has no effect on either mitochondrial respiration or ATP generation. RK-33 curbs proliferation and induces apoptosis in a DDX3-dependent fashion. Wnt signaling is mediated by DDX3 and inhibited by RK-33. RK-33 impairs radiation-induced DNA damage repair by inhibiting NHEJ activity[1]. |
體內(nèi)活性 | RK-33 in combination with radiation induces tumor regression in multiple mouse models of lung cancer. RK-33, at the dose used, is non-toxic in SCID mice. RK-33-treated mice do not exhibit any discernable morphological changes[1]. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 79 mg/mL (184.4 mM) |
關(guān)鍵字 | RK33 |
相關(guān)產(chǎn)品 | Revaprazan hydrochloride | Ibuprofen | Paradol | Glafenine | trans-Cinnamaldehyde | Acetaminophen | Diclofenac Potassium | Indomethacin sodium hydrate | Salicylamide | Salicylic acid | Bismuth Subsalicylate | Diclofenac sodium |
相關(guān)庫(kù) | 抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌化合物庫(kù) | 已知活性化合物庫(kù) | 神經(jīng)信號(hào)分子庫(kù) | 細(xì)胞凋亡化合物庫(kù) | 抗衰老化合物庫(kù) | NO PAINS 化合物庫(kù) | 疼痛相關(guān)化合物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥25 |
VIP8年
|
成都云?;び邢薰?/div>
|
2025-02-08 | |
詢(xún)價(jià) |
VIP4年
|
河源廣譜生物技術(shù)有限公司
|
2025-02-06 | |
詢(xún)價(jià) |
VIP10年
|
上海升德醫(yī)藥科技有限公司
|
2025-01-03 | |
¥1127.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |